申请人:NPS PHARMACEUTICALS, INC.
公开号:EP1281702A2
公开(公告)日:2003-02-05
Method and composition useful for treating a patient having a disease characterized by an abnormal level of one or more components, the activity of which is regulated or affected by activity of one or more Ca2+ receptors. Novel compounds useful in these methods and compositions are also provided. The method includes administering to the patient a therapeutically effective amount of a molecule active at one or more Ca2+ receptors as an agonist or antagonist. Preferably, the molecule is able to act as either a selective agonist or antagonist at a Ca2+ receptor of one or more but not all cells chosen from the group consisting of parathyroid cells, bone osteoclasts, juxtaglomerular kidney cells, proximal tubule kidney cells, keratinocytes, parafollicular thyroid cells and placental throphoblasts and a pharmaceutically acceptable carrier.
用于治疗以一种或多种成分水平异常为特征的疾病患者的方法和组合物,这些成分的活性受一种或多种 Ca2+ 受体活性的调节或影响。还提供了对这些方法和组合物有用的新型化合物。该方法包括向患者施用治疗有效量的对一种或多种 Ca2+ 受体有活性的分子作为激动剂或拮抗剂。优选地,该分子能够作为一种或多种但并非所有细胞的 Ca2+ 受体的选择性激动剂或拮抗剂,这些细胞选自由甲状旁腺细胞、骨破骨细胞、并肾小球肾细胞、近端肾小管肾细胞、角质形成细胞、甲状腺滤泡旁细胞和胎盘滋养细胞组成的组以及药学上可接受的载体。